Long-term functional and quality-of-life outcomes after IPAA in children.

BACKGROUND: The impact of IPAA on long-term outcomes in adults is favorable. Studies on functional outcome and quality of life in children are sparse. OBJECTIVE: The aim of this study was to evaluate the functional and quality-of-life outcomes after IPAA in children and to investigate the possible correlations between the two. DESIGN: Standardized validated questionnaires of bowel/psychosocial functioning and quality of life were used to assess outcome. SETTING: This study was conducted at a tertiary medical center. PATIENTS: All children who had surgery at <18 years of age and were followed up at our institute were included. Global Assessment of Function Scale questionnaires were used to evaluate functional outcome. Quality of life in patients >18 years at the time of follow-up was scored by using the Short Form 36 questionnaire completed by the patients. Quality of life in the younger patients at the time of follow-up was scored using the Child Health Questionarie-28 filled by the parents. RESULTS: Data were obtained in 26 patients (25 with a preoperative diagnosis of ulcerative colitis) at a median follow-up of 6 years. The median age at surgery was 15 years. Quality of life was comparable to the general population for children >18 at the time of follow-up in 7 of 8 items, but was lower than in the general population in 7 of 12 items for those who were younger at the time of follow-up. The mean functional score was found to be negatively correlated to all 8 Short Form 36 parameters (r > 0.5; p < 0.005), but only to one of the Child Health Questionarie-28 parameters. LIMITATIONS: This study was limited by its small sample size. CONCLUSIONS: The functional outcomes among pediatric patients undergoing IPAA are good. Parents' perception of their child's quality of life is poorer in comparison with the perception by patients themselves when older and with no correlation to the functional results.

Experimental repair of tracheal defects using a new biodegradable membrane.

BACKGROUND: The increasing number of newborns requiring intubation and artificial ventilation in the sophisticated premature and intensive care units of recent years has been followed by a concomitant increase in the number of children who develop tracheal stenosis as a sequela of prolonged intubation, with a consequent increasing need for tracheal surgical repair. This study was designed to evaluate the ability of a new tissue-engineered biodegradable membrane to tightly seal significant tracheal defects. MATERIALS AND METHODS: A surgically induced tracheal defect of 10 x 5 mm was repaired in rabbits using the NVR-7 membrane--a cross-linked copolymer derived from a dextran sulphate gelatin construct. The unique features of this new membrane are biocompatibility, biodegradability, elasticity, and suturability, as well as a smooth sterilization process. The animals were sacrificed and the tracheas examined at 2, 3, 4, and 8 weeks postsurgery. RESULTS: Seven (7) of 8 rabbits undergoing tracheal surgery survived, with a tight air seal and an almost normal airway. Macroscopic and microscopic studies of the removed specimens showed variable degrees of immunogenic reaction toward the membrane. In the long term (2-3 months), a complete regeneration of all the tracheal layers occurred, simulating the original structure and orderly arrangement of a normal trachea. CONCLUSIONS: The surgical correction using the above membrane enabled the operated animals to overcome any respiratory distress, adequately correcting the induced tracheal defect. From this experimental study, we conclude that the new NVR-7 membrane appears to be a promising therapeutic adjunct in the treatment of patients with tracheal defects.

Treatment of airway obstruction by metallic stents in infants and children.

OBJECTIVE: The internal metallic stent is a relatively new and controversial method for the treatment of airway collapse in infants and children. The study examined the outcomes of this treatment in a large group of patients and defined clear indications for airway stenting. METHODS: A retrospective review was conducted of 32 patients in whom 42 stents were inserted. The patients were divided into three groups with respect to the stented segment: group A, trachea (n = 14); group B, bronchi (n = 16); and group C, trachea and bronchi (n = 2). RESULTS: In 30 cases, there was immediate improvement of respiratory obstruction, and 23 patients could be weaned, at least temporarily, from ventilation. Excessive granulation developed after the stenting in 26 patients. In 6 patients, all in group A, the granulation and inflammatory reaction generated severe airway obstruction, necessitating thoracotomy in 2 cases. One patient died of airway obstruction, and another died during the attempt to remove the stent; both were in group A. Stents placed for 2 to 72 months (mean 8.7 months) have now been removed in 11 patients. Six children are alive and well with stents in place, 2 from group A and 4 from group B. Fifteen patients died during the follow-up period; in 13 cases, death was related to the associated disease. CONCLUSION: The use of metallic stents, especially in the trachea, is associated with a high rate of complications. Granulation tissue, which often develops after stenting, is a major concern. Removal of the stents is arduous and carries a high risk of complications. The use of stents should be restricted to the limited situations in which conventional initial therapy has failed.

Tracheal reaction to three different intraluminal stents in an animal model of tracheomalacia.

Three different internal airway stents were studied in an animal model of tracheomalacia: the Palmaz stent (Johnson & Johnson, Warren, New Jersey) and the NIR stent (Medinol Ltd., Tel Aviv, Israel)--both made of stainless steel in the form of tubular mesh--and the Nitinol stent, made of nickel-titanium formed into a spiral shape. All three stents could be adequately stabilized in the malacic tracheal segment. The Nitinol stent (Medinol Ltd., Tel Aviv, Israel) proved to be less reactive to the tracheal mucosa, demonstrated higher biocompatibility with significantly less granulation tissue formation, and showed superior radial resistance. Extraction of the Nitinol stent also proved to be much smoother. This stent may be the stent of choice in the treatment of tracheo- and bronchomalacia.